Dengue - Pipeline Insight, 2024

This “Dengue- Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Dengue pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dengue Understanding

Dengue: Overview

Dengue is a mosquito-transmitted virus and the leading cause of arthropod-borne viral disease in the world. It is also known as breakbone fever due to the severity of muscle spasms and joint pain, dandy fever, or seven-day fever because of the usual duration of symptoms. Although most cases are asymptomatic, severe illness and death may occur. Aedes mosquitoes transmit the virus and are common in tropical and subtropical parts of the world. The incidence of dengue has increased dramatically over the past few decades, and the infection is now endemic in some parts of the world. A few people who were previously infected with one subspecies of the dengue virus develop severe capillary permeability and bleeding after being infected with another subspecies of the virus. This illness is known as dengue hemorrhagic fever. It is the fastest spreading mosquito-borne viral disease globally, affecting greater than 100 million humans annually. Dengue also causes 20 to 25,000 deaths, primarily in children, and is found in more than 100 countries. Mild symptoms of dengue can be confused with other illnesses that cause fever, aches and pains, or a rash. The most common symptom of dengue is fever with any of the following: Nausea, vomiting, rash, aches and pains (eye pain, typically behind the eyes, muscle, joint, or bone pain). The clinical diagnosis of dengue can be challenging as many other illnesses can present similarly early in the disease course. Other considerations should include malaria, influenza, Zika, chikungunya, measles, and yellow fever. Untreated severe dengue fever may have a mortality rate of 10% to 20%. Appropriate supportive care reduces the mortality rate to roughly 1%. The only way to avoid contracting dengue is to prevent mosquito bites and not travel to endemic areas. There is no specific medicine to treat dengue.

Dengue- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dengue pipeline landscape is provided which includes the disease overview and Dengue treatment guidelines. The assessment part of the report embraces, in depth Dengue commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dengue collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dengue R&D. The therapies under development are focused on novel approaches to treat/improve Dengue.

Dengue Emerging Drugs Chapters

This segment of the Dengue report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dengue Emerging Drugs

VIS 513: Visterra VIS513, is a monoclonal antibody in development for the treatment of Dengue, a serious mosquito-borne virus, which in its most severe forms is characterized by uncontrolled bleeding leading to organ failure and death. VIS513 has in vitro and in vivo activity against all four Dengue virus serotypes foundglobally.

TAK-003: Takeda Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses. Clinical Phase II data in children and adolescents showed that TAK-003 induced immune responses against all four dengue serotypes, in both seropositive and seronegative participants, which persisted through 48 months after vaccination, and the vaccine was found to be generally safe and well tolerated. The pivotal Phase 3 TIDES trial met its primary endpoint of overall vaccine efficacy (VE) against virologically confirmed dengue (VCD) at 12 months follow-up and all secondary endpoints at 18 months follow-up for which there were a sufficient number of dengue cases, including VE against hospitalized dengue and VE in baseline seropositive and baseline seronegative individuals. The results demonstrated TAK-003 was generally well tolerated, and there have been no important safety risks observed to date.Takeda announced that the European Medicines Agency (EMA) has accepted the Company’s filing packages for its dengue vaccine candidate (TAK-003) which is being investigated for the prevention of dengue due to any dengue virus serotype in individuals ages four to60.

CDX DENV: Codagenix Codagenix has leveraged the platform to re-design contemporary strains of dengue and demonstrate a balanced tetravalent vaccine that is safe and immunogenic in primates. CDX DENV, is a Synthetic vaccine being developed in the Pre-Clinical stage for the treatment ofDengue.

AT 752: Atea Pharmaceuticals AT-752, a diastomer of AT-527, is a novel purine nucleotide prodrug, designed to treat patients either newly infected or previously infected with the dengue virus. AT-752 has an favorable preclinical safety profile and has demonstrated potent in vitro activity against all dengue serotypes tested as well as potent antiviral activity in predictive animal models. Atea Pharmaceuticals plan to conduct clinical studies that will evaluate the daily administration of AT-752 over a short period of treatment, in order to negate the progression of infection and reduce the occurrence of life-threatening conditions associated with severe dengue.

Dengue: Therapeutic Assessment

This segment of the report provides insights about the different Dengue drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dengue

There are approx. 20+ key companies which are developing the therapies for Dengue. The companies which have their Dengue drug candidates in the most advanced stage, i.e. Pre-Regisration include, Takeda.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Dengue pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dengue: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dengue therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dengue drugs.

Dengue Report Insights

• Dengue Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dengue Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dengue drugs?
• How many Dengue drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dengue?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dengue therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dengue and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Visterra
• Takeda
• Codagenix
• Atea Pharmaceuticals
• Abivax
• Janssen Research & Development
• Plex Pharmaceuticals

Key Products

• VIS 513
• TAK-003
• CDX DENV
• AT 752
• ABX 220
• JNJ-64281802
• TV003

Research programme: infectious diseases therapeutics


This product will be delivered within 1-3 business days.